In This Section

Dah-Jyuu Wang, PhD
Dah-Jyuu Wang
Chief, MR Spectroscopy

Dr. Wang works on biomarker identification using multiparametric magnetic resonance imaging and homo- and hetero-nuclear spectroscopy techniques for pediatric disease research including  tumors, iron overload, cystic fibrosis, muscular dystrophy, autism, mitochondrial, Gaucher’s, and Canavan’s diseases.



Subscribe to be notified of changes or updates to this page.

13 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.


Dr. Wang has extensive training and expertise in the field of pediatric magnetic resonance imaging (MRI) and spectroscopy. He's experienced in studying perfused cells/organs, and animal and human models using multiparametric MRI and MRS techniques. For the past 18 years, he has been active in pediatric MRI/MRS research.

Dr. Wang was the CHOP site PI for a multi-centered “NIH MRI Study of Normal Brain Development” using volumetric, T1-mapping, DTI, and MRS technologies. He has collaborated with CHOP and outside institutions in several local and nationwide research studies as an investigator, studying a range of disorders including tumors, iron overload, cystic fibrosis, muscular dystrophy, autism, mitochondrial, and Gaucher’s and Canavan’s diseases.

His current research interests focus on biomarker identification using quantitative 1H, 31P, 13C and 129Xe MRS and MRI, such as T2 mapping, Dixon, and CrCEST (Creatine Chemical Exchange Saturation Transfer) Techniques.

Education and Training

BS, Tamkang University, Taiwan (Chemistry),  1979

MS, Stony Brook University, New York (Physical Chemistry, MRI), 1986

PhD, Stony Brook University, New York (Physical Chemistry, MRI/MRS), 1989

Postdoctoral Research Fellow, Metabolic Magnetic Resonance Research and Computing Center, Department of Radiology, University of Pennsylvania, 1989

Titles and Academic Titles

Chief, MR Spectroscopy

Research Assistant Professor, University of Pennsylvania

Professional Memberships

International Society for Magnetic Resonance in Medicine, 2001-

Publication Highlights

Degnan AJ, Ho-Fung VM, Ahrens-Nicklas RC, Barrera CA, Serai SD, Wang DJ, Ficicioglu C. Imaging of non-neuronopathic Gaucher disease: recent advances in quantitative imaging and comprehensive assessment of disease involvement, Insights Imaging. Insights Imaging. 2019 Jul; 10(1):70. PubMed PMID: 31289964
Port RG, Gaetz W, Bloy L, Wang DJ, Blaskey L, Kuschner ES, Levy SE, Brodkin ES, Roberts TP. Exploring the relationship between cortical GABA concentrations, auditory gamma-band responses and development in ASD: Evidence for an altered maturational trajectory in ASD. Autism Res. 2017 Apr; 10(4):593-607. doi: 10.1002/aur.1686. Epub 2016 Oct 1
Willcocks RJ, Rooney WD, Triplett WT, Forbes SC, Lott DJ, Senesac CR, Daniels MJ, Wang DJ, Harrington AT, Tennekoon GI, Russman BS, Finanger EL, Byrne BJ, Finkel RS, Walter GA, Sweeney HL, Vandenborne K. Multicenter Prospective Longitudinal Study of Magnetic Resonance Biomarkers in a Large Duchenne Muscular Dystrophy Cohort. Ann Neurol. 2016 Apr; 79(4):535-47. PubMed PMID 26891991
Walker L, Chang LC, Nayak A, Irfanoglu MO, Botteron KN, McCracken J, McKinstry RC, Rivkin MJ, Wang DJ, Rumsey J, Pierpaoli C, Brain Development Cooperative Group. The Diffusion Tensor Imaging (DTI) Component of the NIH MRI Study of Normal Brain Development (PedsDTI). Neuroimage. 2016 Jan; 124(Pt B):1125-1130. PubMed PMID 26048622
Leone P, Shera D, McPhee SWJ, Francis JS, Kolodny EH, Bilaniuk LT, Wang DJ, Assadi M, Goldfarb O, Goldman HW, Freese A, Young D, During MJ, Samulski RJ, Janson CG. Long-Term Follow-Up After Gene Therapy for Canavan Disease. Sci Transl Med. 2012 Dec; 4(165):165ra163. PubMed PMID 23253610

Active Grants/Contracts

Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy

  • National Institutes of Health
  • 2015 - 2020
  • The objectives of this study is to validate the potential of noninvasive magnetic resonance imaging and spectroscopy to monitor disease progression and to serve as a surrogate outcome measure for clinical trials in Duchenne muscular dystrophy.
  • Principal Investigator: Vandenborne

Magnetic Resonance Clinical Trial

  • Italfarmaco Study sponsored by University of Florida
  • 2016 -2020
  • A randomized, double blind, placebo controlled, multicenter study to evaluate the efficacy and safety of givinostat in ambulant patients with Duchenne muscular dystrophy .
  • Subcontract Principal Investigator: Wang

NAD+ Precursor Supplementation with Exercise Training to Improve Aerobic Capacity in Friedreich's Ataxia.

  • National Institutes of Health
  • 2020 - 2024
  • Principal Investigator: McCormack

Friedreich Ataxia in Children

  • U.S. Food and Drug Administration
  • 2017 - 2022
  • Principal Investigator: Lynch